Floatz logo

JCAR-017 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR

Diffuse Large B-Cell Lymphoma

Lyell Immunopharma, Inc.Cell therapyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
81/ 100

Competitive context

252 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Vincristine sulfate
National Cancer Institute (NCI)
Phase 2/3A
MELPHALAN
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
Adriamycin
Beth Israel Deaconess Medical Center
Phase 4BBB
Nivestim
Ruijin Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

JCAR-017 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR is also rated in:

non-Hodgkin lymphomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
primary mediastinal large B-cell lymphomaActive
BB
Indicative · Phase 2
65 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →